tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Neurocrine sees FY24 Ingrezza revenue $2.300B-$2.320B

Sees FY24 Non-GAAP R&D Expense $635M-$655M and Non-GAAP SG&A Expense $825M-$845M.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1